Literature DB >> 15954137

Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Daniel Weintraub1, Knashawn H Morales, Paul J Moberg, Warren B Bilker, Catherine Balderston, John E Duda, Ira R Katz, Matthew B Stern.   

Abstract

The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta-analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta-analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. (c) 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954137      PMCID: PMC1989731          DOI: 10.1002/mds.20555

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  49 in total

1.  The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients.

Authors:  G S Alexopoulos; I R Katz; C F Reynolds; D Carpenter; J P Docherty
Journal:  Postgrad Med       Date:  2001-10       Impact factor: 3.840

2.  Depression in Parkinson's disease. The impact of symptom overlap on prevalence.

Authors:  W J Hoogendijk; I E Sommer; G Tissingh; D J Deeg; E C Wolters
Journal:  Psychosomatics       Date:  1998 Sep-Oct       Impact factor: 2.386

3.  SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

Authors:  G Dell'Agnello; R Ceravolo; A Nuti; G Bellini; A Piccinni; C D'Avino; L Dell'Osso; U Bonuccelli
Journal:  Clin Neuropharmacol       Date:  2001 Jul-Aug       Impact factor: 1.592

4.  Desipramine in treatment of Parkinson's disease. A placebo-controlled study.

Authors:  L Laitinen
Journal:  Acta Neurol Scand       Date:  1969       Impact factor: 3.209

5.  Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism.

Authors:  P A Fischer; H Baas
Journal:  J Neural Transm Suppl       Date:  1987

6.  Risk factors for depression in Parkinson disease.

Authors:  E Tandberg; J P Larsen; D Aarsland; K Laake; J L Cummings
Journal:  Arch Neurol       Date:  1997-05

7.  An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.

Authors:  Lon S Schneider; J Craig Nelson; Cathryn M Clary; Paul Newhouse; K Ranga Rama Krishnan; Thomas Shiovitz; Karen Weihs
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

8.  Depression in Parkinson's disease.

Authors:  S E Starkstein; T J Preziosi; P L Bolduc; R G Robinson
Journal:  J Nerv Ment Dis       Date:  1990-01       Impact factor: 2.254

9.  Treatment of depression in Parkinson's disease: a meta-analysis.

Authors:  T Klaassen; F R Verhey; G H Sneijders; N Rozendaal; H C de Vet; H M van Praag
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1995       Impact factor: 2.198

Review 10.  The placebo effect in Parkinson's disease.

Authors:  Raúl de la Fuente-Fernández; A Jon Stoessl
Journal:  Trends Neurosci       Date:  2002-06       Impact factor: 13.837

View more
  47 in total

Review 1.  Recognition and management of neuropsychiatric complications in Parkinson's disease.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  CMAJ       Date:  2006-12-05       Impact factor: 8.262

Review 2.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study.

Authors:  Katherine Oehlberg; Frances K Barg; Gregory K Brown; Donna Taraborelli; Matthew B Stern; Daniel Weintraub
Journal:  J Geriatr Psychiatry Neurol       Date:  2008-06       Impact factor: 2.680

Review 4.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

5.  Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.

Authors:  D Weintraub; S Mavandadi; E Mamikonyan; A D Siderowf; J E Duda; H I Hurtig; A Colcher; S S Horn; S Nazem; T R Ten Have; M B Stern
Journal:  Neurology       Date:  2010-08-03       Impact factor: 9.910

6.  Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample.

Authors:  Peijun Chen; Helen C Kales; Daniel Weintraub; Frederic C Blow; Lan Jiang; Alan M Mellow
Journal:  J Geriatr Psychiatry Neurol       Date:  2007-09       Impact factor: 2.680

7.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

Review 8.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

Review 9.  Psychiatric symptoms in Parkinson's disease.

Authors:  Frank Schneider; Astrid Althaus; Volker Backes; Richard Dodel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

Review 10.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Petros Skapinakis; Eleni Bakola; Georgia Salanti; Glyn Lewis; Athanasios P Kyritsis; Venetsanos Mavreas
Journal:  BMC Neurol       Date:  2010-06-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.